ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
06 November 2023 - 11:05PM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
publication of an article in the peer-reviewed journal,
Ecotoxicology and Environmental Safety, demonstrating that
inhibiting NLRP3 inflammasomes can attenuate kidney damage and
dysfunction associated with the environmental pollutant, PM2.5.
In the paper titled, “PM2.5 induces renal tubular
injury by activating NLRP3-mediated pyroptosis,” the authors
conducted studies in a mouse model exposed to high concentrations
of ambient PM2.5 for 12 weeks, and in a mouse kidney cell line.
Following are key findings reported in the paper:
- PM2.5 exposure leads to kidney
structural changes and functional impairment.
- Inflammasome NLRP3-induced
Inflammation and pyroptosis were increased in PM2.5-exposed kidney
tissues.
- Inhibiting the inflammasome NLRP3
pathway, including downstream caspase-1, rescued the kidneys from
PM2.5-induced cell death.
The authors stated, “We further provided evidence
that NLRP3-mediated pyroptosis plays critical roles in the
progression of kidney injury induced by PM2.5 exposure. Inhibiting
the activation of NLRP3 inflammasome can remarkably protect the
renal tubular epithelial cells from PM2.5-induced proptosis.” To
read the article, Click Here.
“The research published in the Journal,
Ecotoxicology and Environmental Safety, reinforces other published
data demonstrating that inhibiting NLRP3 inflammasomes can
attenuate kidney damage and dysfunction of multiple causes, now
including kidney damage associated with the environmental
pollutant, PM2.5,” commented Stephen C. Glover, ZyVersa’s
Co-founder, Chairman, CEO and President. “This research provides
increasing support for inflammasome inhibition as a promising
treatment option for kidney disease, a major health problem
affecting over 35 million adults in the United States. ZyVersa is
developing Inflammasome ASC inhibitor IC 100. Unlike NLRP3
inhibitors, designed to inhibit formation of one inflammasome to
block initiation of the inflammatory cascade, IC 100 was designed
to inhibit multiple types of inflammasomes and their associated ASC
specks to uniquely block both initiation and perpetuation of
damaging inflammation.” To review a white paper summarizing the
mechanism of action and preclinical data for IC 100, Click
Here.
About Inflammasome ASC Inhibitor IC
100
IC 100 is a novel humanized IgG4 monoclonal
antibody that inhibits the inflammasome adaptor protein ASC. IC 100
was designed to attenuate both initiation and perpetuation of the
inflammatory response. It does so by binding to a specific region
of the ASC component of multiple types of inflammasomes, including
NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100
binds to ASC monomers, inhibiting inflammasome formation, thereby
blocking activation of IL-1β early in the inflammatory cascade. IC
100 also binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics,
Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage
specialty biopharmaceutical company leveraging advanced,
proprietary technologies to develop first-in-class drugs for
patients with renal and inflammatory diseases who have significant
unmet medical needs. The Company is currently advancing a
therapeutic development pipeline with multiple programs built
around its two proprietary technologies – Cholesterol Efflux
Mediator™ VAR 200 for treatment of kidney diseases, and
Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation
associated with numerous CNS and other inflammatory diseases. For
more information, please visit www.zyversa.com.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements contained in this press release
regarding matters that are not historical facts, are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995. These include statements
regarding management’s intentions, plans, beliefs, expectations, or
forecasts for the future, and, therefore, you are cautioned not to
place undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not
possible for ZyVersa to predict all such factors, nor can ZyVersa
assess the impact of each such factor on the business or the extent
to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Forward-looking statements included in
this press release are based on information available to ZyVersa as
of the date of this press release. ZyVersa disclaims any obligation
to update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to
sell, or the solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen
CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave
Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024